The local biotech ecosystem is growing up thanks to its innovative science and collaborative ecosystem, advantages that put it nearly on par with the nation’s top life science regions, according to industry veterans.

San Diego has long been considered a second-tier primary biopharma hub in terms of number of companies and venture capital raised, falling behind the twin behemoths of Boston-Cambridge and the San Francisco Bay Area on those and other metrics.

At Xconomy’s Xcelerating Life Sciences San Diego event this month, investors, executives, and others noted under-looked strengths contributing to the region’s maturation.

Venture capitalist Nancy Hong recalled that some… Read more »